NADH (nicotinamide adenine dinucleotide hydride) is the reduced form of NAD+, a critical coenzyme involved in cellular energy production, redox reactions, and mitochondrial function. It plays a fundamental role in ATP synthesis through oxidative phosphorylation and serves as an electron carrier in metabolic pathways. NADH is investigated for its potential to enhance cellular energy, combat age-related NAD+ decline, and support cognitive and physical performance.

Overview

NADH (nicotinamide adenine dinucleotide, reduced form) is the electron-carrying coenzyme that occupies a central position in cellular energy metabolism. As the primary electron donor to Complex I (NADH:ubiquinone oxidoreductase) of the mitochondrial electron transport chain, NADH drives the process of oxidative phosphorylation that generates approximately 90% of cellular ATP. Each molecule of NADH delivers two electrons that ultimately contribute to the production of 2.5 ATP molecules via the proton gradient across the inner mitochondrial membrane. NADH is generated by the citric acid cycle (TCA cycle), beta-oxidation of fatty acids, and glycolysis, making it the metabolic currency that links macronutrient catabolism to energy production. The NAD+/NADH ratio is a critical determinant of cellular redox state and metabolic efficiency, influencing everything from sirtuin enzyme activity to reactive oxygen species generation.

The therapeutic rationale for NADH supplementation centers on conditions characterized by impaired mitochondrial function and energy deficiency. In chronic fatigue syndrome (CFS/ME), a randomized double-blind placebo-controlled trial demonstrated that sublingual NADH (20 mg daily) significantly reduced fatigue and improved cognitive function compared to placebo, with response rates of approximately 30% versus 8%. The proposed mechanism involves direct enhancement of mitochondrial ATP production and restoration of depleted cellular energy reserves. In neurodegenerative disease research, NADH supplementation has been investigated for Alzheimer's disease and Parkinson's disease, based on the well-documented mitochondrial dysfunction and Complex I deficiency in these conditions. A clinical study in Alzheimer's patients showed cognitive improvement with NADH treatment, potentially mediated by enhanced dopamine, norepinephrine, and serotonin biosynthesis — NADH serves as a cofactor for tyrosine hydroxylase and tryptophan hydroxylase, the rate-limiting enzymes in catecholamine and serotonin synthesis, respectively.

NADH supplements are typically available in stabilized sublingual tablets (5–20 mg) designed to bypass gastric degradation, as the reduced form is highly sensitive to oxidation and acid hydrolysis. Enteric-coated oral formulations are also available. NADH is functionally related to but distinct from NAD+ precursors such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), which aim to increase total NAD+ pools rather than directly supplying the reduced electron-carrying form. In comprehensive mitochondrial support protocols, NADH is often combined with CoQ10 (which accepts electrons from Complex I and Complex II), PQQ (which stimulates mitochondrial biogenesis), and alpha-lipoic acid for synergistic bioenergetic enhancement. Side effects are rare at typical supplemental doses.

Mechanism of Action

Central Role in Energy Metabolism

NADH (reduced nicotinamide adenine dinucleotide) is the primary electron carrier in cellular energy metabolism. It is generated in catabolic pathways — glycolysis (cytoplasmic), the tricarboxylic acid (TCA/Krebs) cycle (mitochondrial matrix), and beta-oxidation of fatty acids — and carries high-energy electrons to the inner mitochondrial membrane for ATP production.

Complex I & Oxidative Phosphorylation

NADH donates its electron pair to Complex I (NADH:ubiquinone oxidoreductase), the largest complex of the electron transport chain (ETC). Complex I transfers electrons through a series of iron-sulfur clusters to ubiquinone (CoQ10), coupling this electron transfer to the pumping of 4 H⁺ ions across the inner mitochondrial membrane. This, combined with proton pumping at Complexes III and IV, generates the electrochemical proton gradient that drives ATP synthase (Complex V) to produce ATP. Each NADH molecule yields approximately 2.5 ATP through oxidative phosphorylation.

Redox Homeostasis

The NAD⁺/NADH ratio is a critical cellular metabolic sensor. A high ratio (oxidized state) favors catabolic, energy-producing pathways, while a low ratio (reduced state) favors anabolic biosynthesis. NADH participates as an electron donor in hundreds of enzymatic reactions catalyzed by oxidoreductases (dehydrogenases, reductases), maintaining redox balance across metabolic compartments. The cytoplasmic and mitochondrial NAD⁺/NADH pools communicate through the malate-aspartate shuttle and glycerol-3-phosphate shuttle.

Dopamine Biosynthesis Support

NADH supports dopamine biosynthesis through its role in regenerating tetrahydrobiopterin (BH4), the essential cofactor for tyrosine hydroxylase (TH) — the rate-limiting enzyme in catecholamine synthesis (tyrosine → L-DOPA → dopamine → norepinephrine → epinephrine). Dihydropteridine reductase (DHPR) uses NADH to reduce dihydrobiopterin (BH2) back to BH4, maintaining TH catalytic activity. Clinical studies in Parkinson's disease patients showed that oral NADH (5-10 mg/day) improved disability ratings, potentially through this BH4/TH mechanism (PMID: 8951275).

Sirtuin & PARP Connection

While NADH itself is not the direct substrate for sirtuins and PARPs (which require NAD⁺), NADH supplementation influences the NAD⁺/NADH ratio and total NAD pool size. Cellular NADH is continuously oxidized back to NAD⁺ by the ETC (Complex I), lactate dehydrogenase, and other oxidoreductases. By increasing the total NAD(H) pool, supplemental NADH may indirectly support SIRT1-7 deacetylase activity (regulating metabolism, inflammation, and longevity gene programs) and PARP DNA repair activity, though this relationship is complex and context-dependent.

Oral Bioavailability Considerations

Oral NADH is susceptible to degradation by gastric acid and enzymatic hydrolysis. Stabilized formulations (enteric-coated, sublingual) are used to improve bioavailability. Once absorbed, NADH enters cells via nucleotide transporters or is metabolized to nicotinamide (NAM) and subsequently resynthesized intracellularly through the salvage pathway (NAM → NMN → NAD⁺ → NADH).

Reconstitution Calculator

Research

Safety Profile

Side effects are uncommon but may include mild jitteriness, anxiety, and insomnia, particularly at higher doses. It is contraindicated in individuals with a known hypersensitivity. People with Parkinson's disease should be cautious, as high doses of NADH may cause symptoms to worsen.

Pharmacokinetic Profile